The European Commission Has Granted Marketing Authorization In Europe For Valneva's Single-dose Vaccine, Ixchiq, For Individuals 18 Years Of Age And Older. The Company Expects To Deliver The First Doses In Europe In Q4 Of 2024
Portfolio Pulse from Benzinga Newsdesk
The European Commission has granted marketing authorization for Valneva's single-dose vaccine, Ixchiq, for individuals 18 years and older. The company expects to deliver the first doses in Europe in Q4 of 2024.
July 01, 2024 | 10:40 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Valneva has received marketing authorization from the European Commission for its single-dose vaccine, Ixchiq, for individuals 18 years and older. The company plans to deliver the first doses in Europe by Q4 2024.
The marketing authorization from the European Commission is a significant milestone for Valneva, potentially boosting its revenue and market presence in Europe. The expected delivery of the first doses by Q4 2024 indicates a clear timeline for revenue generation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100